Osteoarthritis and Bone Disorders News

EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.

Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.

Researchers and CEOs alike presented data recently at a “Shark Tank”-like session with lawmakers on Capitol Hill to discuss, and seek federal funding for, potential therapies for osteoarthritis.

Postmenopausal women with osteoporosis who use denosumab as a first-line therapy have lowers risk for fractures compared with women who use alendronate, according to an industry press release.

The FDA granted orphan drug designation and rare pediatric disease designation for a therapy to treat a rare pediatric skeletal disorder, according to an industry press release.

The Secondary Prevention Task Group of the Osteoarthritis Action Alliance released 15 recommendations for the prevention of osteoarthritis after an ACL injury, according to a press release from the National Athletic Trainers Association.

SEATTLE — Among men aged at least 40 years who experienced a fracture, most with subsequent fractures in the next 2 years had cardiometabolic comorbidities and used medications linked to increased fall risk, according to researchers.

Patients with gout who achieve and maintain target serum urate levels through urate-lowering therapy demonstrate a reduced risk for fractures, according to data published in Arthritis & Rheumatology.

Patients with atopic diseases may be at an increased risk for developing osteoarthritis, according to data published in Annals of the Rheumatic Diseases.

Physicians who receive industry payments are more likely to administer hyaluronic acid injections, as well as an increased volume of injections, for osteoarthritis despite questionable benefit, according to data.